CAS 2289690-31-7

MYCi361

CAS: 2289690-31-7

MYCi361 (NUCC-0196361) is an inhibitor of MYC (binding to MYC with Kd of 3.2 μM).

Fórmula: C₂₆H₁₆ClF₉N₂O₂

Pureza: 99.52%

Cor e Forma: Solid

Peso molecular: 594.86

Ref: TM-T12132

6-((4-Chlorobenzyl)oxy)-3-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-3',5'-bis(trifluoromethyl)-[1,1'-biphenyl]-2-ol

CAS: 2289690-31-7

Fórmula: C₂₆H₁₆ClF₉N₂O₂

Pureza: 98%

Cor e Forma: Solid

Peso molecular: 594.8561

Ref: IN-DA01KKRS

6-((4-Chlorobenzyl)Oxy)-3-(1-Methyl-3-(Trifluoromethyl)-1H-Pyrazol-5-Yl)-3',5'-Bis(Trifluoromethyl)-[1,1'-Biphenyl]-2-Ol

CAS: 2289690-31-7

6-((4-Chlorobenzyl)Oxy)-3-(1-Methyl-3-(Trifluoromethyl)-1H-Pyrazol-5-Yl)-3',5'-Bis(Trifluoromethyl)-[1,1'-Biphenyl]-2-Ol

Pureza: 98%

Peso molecular: 594.86g/mol

Ref: 54-PC108426

MYCi361

CAS: 2289690-31-7

MYCi361

Pureza: ≥98%

Peso molecular: 594.86g/mol

Ref: 54-BUP01412

MYCi361

CAS: 2289690-31-7

MYCi361 is an antibody-drug conjugate that targets the histone deacetylase. MYCi361 has been shown to be effective in treating leukocyte antigen (HLA)-expressing tumours, such as melanoma, colorectal cancer, and breast cancer that overexpress the HER2 receptor. MYCi361 blocks the biological activity of histone deacetylase by binding to it, which results in reduced expression of HLA proteins. This leads to tumor regression and prolonged survival in animal models.

Fórmula: C₂₆H₁₆ClF₉N₂O₂

Pureza: Min. 95%

Peso molecular: 594.9 g/mol

Ref: 3D-PRD69031